Human iPSC models of myocardial infarction: From injury to repair and therapeutic discovery
- 1Department of Anatomy and Embryology, Leiden University Medical Center, 2300RCLeiden, the Netherlands
- 2The Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, Leiden University Medical Center, 2300RC Leiden, the Netherlands
Abstract
Myocardial infarction (MI) remains a leading cause of death worldwide, and therapies that limit injury, promote repair, and restore cardiac function remain limited. Human induced pluripotent stem cells (hiPSCs) provide a renewable source of patient-specific cardiac cells and have enabled the development of increasingly complex in vitro models that incorporate cardiomyocytes together with supporting stromal and vascular cell types. These models are now being used to study multiple stages of MI pathophysiology and are increasingly being applied in therapeutic discovery and regenerative strategies. In this review, we summarize hiPSC-based cardiac models spanning 2D cultures to advanced 3D tissues, organoids, and heart-on-chip systems, evaluating how well they capture key features of human MI. We further discuss hiPSC applications in therapeutic discovery, drug screening, precision medicine, and regenerative repair. Finally, we highlight priorities for the field, including improved physiological complexity, stronger translational robustness, bioengineering strategies, and integration with multi-omics.
Related
- Stress hyperglycemia impairs FOXK2-dependent macrophage cardiac repair after myocardial infarction
- Cardiomyocyte-specific deletion of thioredoxin promotes myocardial injury, infarction and mitochondrial dysfunction: translocation of cytosolic thioredoxin into mitochondria rescue myocardial dysfunction by restoration of cardiac mitochondrial structure and function.
- HSP90B1 exacerbates myocardial infarction injury by promoting cardiomyocyte pyroptosis and is associated with M1-like macrophage polarization
- The NLRP3 inflammasome as a bridge between myocardial infarction and depression: mechanisms, bidirectional link, and therapeutic potential
- Pyroptosis in myocardial ischemia-reperfusion injury: mechanistic pathways and therapeutic prospects.
BibTeX
@article{johnson2026human,
title = {{Human iPSC models of myocardial infarction: From injury to repair and therapeutic discovery}},
author = {Benjamin B. Johnson and Christine L. Mummery and Richard P. Davis},
journal = {Cell Reports Medicine},
year = {2026},
month = sep,
doi = {10.1016/j.xcrm.2026.103079},
url = {https://doi.org/10.1016/j.xcrm.2026.103079},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Human iPSC models of myocardial infarction: From injury to repair and therapeutic discovery
AU - Benjamin B. Johnson
AU - Christine L. Mummery
AU - Richard P. Davis
PY - 2026
DA - 2026/09/25
JO - Cell Reports Medicine
DO - 10.1016/j.xcrm.2026.103079
UR - https://doi.org/10.1016/j.xcrm.2026.103079
AB - Myocardial infarction (MI) remains a leading cause of death worldwide, and therapies that limit injury, promote repair, and restore cardiac function remain limited. Human induced pluripotent stem cells (hiPSCs) provide a renewable source of patient-specific cardiac cells and have enabled the development of increasingly complex in vitro models that incorporate cardiomyocytes together with supporting stromal and vascular cell types. These models are now being used to study multiple stages of MI pathophysiology and are increasingly being applied in therapeutic discovery and regenerative strategies. In this review, we summarize hiPSC-based cardiac models spanning 2D cultures to advanced 3D tissues, organoids, and heart-on-chip systems, evaluating how well they capture key features of human MI. We further discuss hiPSC applications in therapeutic discovery, drug screening, precision medicine, and regenerative repair. Finally, we highlight priorities for the field, including improved physiological complexity, stronger translational robustness, bioengineering strategies, and integration with multi-omics.
SN - 2666-3791
ER -